Gilead Sciences (GILD) Stock | Do I Smell Low Cost Opportunity?

Gilead Sciences, Inc (NASDAQ: GILD) When it comes to the biotech sector, Gilead Sciences is one of the most talked about stocks; and for good reason. It’s arguably the most interesting success story in biotech to date! The company has taken full control of both the HIV treatment market and the HCV treatment market; however, … Read more

Gilead Sciences (GILD) Stock Declines On HCV Sales Issues

Gilead Sciences, Inc. (NASDAQ: GILD) | AbbVie Inc. (NYSE: ABBV) Gilead Sciences has made a major name for itself in the healthcare market; taking the hepatitis C virus and HIV treatment markets by storm. However, AbbVie has recently stepped in to challenge Gilead’s position in the HCV market; and unfortunately we’re seeing a decline in … Read more

Why Gilead Sciences Should Buy Out Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) | Gilead Sciences, Inc. (NASDAQ: GILD) Yesterday, major rumors started to fly around in market talk that Gilead Sciences was planning on acquiring Gilead Sciences. The rumors started because both ACHN and GILD were believed to have missed the UBS conference scheduled yesterday. While some may be pointing to the … Read more

Gilead (GILD) | AbbVie (ABBV) | Breaking Down The HCV Pricing Battle

Gilead Sciences, Inc. (NASDAQ: GILD) AbbVie Inc (NYSE: ABBV) Before I get into the details, this article was written as a request from Ward Agular Financial Inc. If you haven’t checked out their website, it’s well worth doing. Click here to check them out! I’ve been following Gilead Sciences for quite some time now; and I have … Read more

Gilead Sciences (GILD) Won’t Be Giving Up The HCV Throne Any Time Soon

Gilead Sciences, Inc. (NASDAQ: GILD) When we talk about Gilead Sciences, the main topic of discussion is HCV. While the company is the leader in treatments for both HCV and HIV, competition in the HCV market became fierce as AbbVie Inc (NYSE: ABBV). However, even with a price war and added competition, GILD still takes … Read more

Gilead Sciences (GILD) HCV Treatment Added To WHO’s “Essential Medicine” List

Gilead Sciences, Inc. (NASDAQ: GILD) Gilead Sciences has been in the midst of an interesting battle with regard to pricing of it’s HCV treatments Harvoni and Sovaldi. While the treatments have been proven to be incredibly effective, they are also incredibly expensive; limiting access to some patients that could greatly benefit from treatment. As a … Read more

Gilead (GILD) Sciences Stock | Another Reason To Invest

Gilead Sciences, Inc. (NASDAQ: GILD) Gilead Sciences is a major player in the biotech space. With a strong hold on the hepatitis C and HIV markets, there’s already plenty of reasons for investors to get excited about the stock. However, yesterday, we learned of a new reason! Gilead Sciences has entered into an agreement to … Read more

Gilead Sciences (GILD) Stock Presents A Great Buying Opportunity

Gilead Sciences, Inc. (NASDAQ: GILD) Following last week’s positive earnings report, Gilead Sciences had a great couple of days in the market. However, the stock is down today and in a big way. While some may be looking at this as tremendously bad news, I see the exact opposite. In my opinion, GILD is doing … Read more

Gilead Sciences (GILD) | AbbVie (ABBV) | What Hep C Patients & Investors Need To Know!

Gilead Sciences, Inc. (NASDAQ: GILD) If you’re a Gilead Sciences follower, patient, or investor, you know what they do. The company is currently the leader in the treatment of hepatitis C. The company’s treatments Harvoni and Sovaldi have incredibly high cure rates, low side effects, and the patient needs to take less medication overall than … Read more

Gilead Sciences (GILD) | Earnings Should Be A Hit!

Gilead Sciences, Inc. (NASDAQ: GILD) Gilead Sciences is expected to release its earnings report today after the bell. So naturally, curiosity strikes and I’ve decided to take a look at what we can expect to see. Here are a few things to keep in mind before the earnings release… GILD HCV Earnings Shouldn’t Be A … Read more